At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Post-Mkt 10-13 16:52:42 EDT
1.26
-0.10
-7.35%
盘后0.9700
-0.29-23.02%
16:52 EDT
High1.44Low1.23Vol6.72M
Open1.44D1 Closing1.36Amplitude15.20%
Mkt Cap91.10MTradable Cap87.80MTotal Shares72.30M
T/O8.42MT/O Rate9.64%Tradable Shares69.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biomea Fusion: in an Additional Fifth Cohort Conducted Under Confinement, at Day 29, Mean Weight Reduction Averaged About 1.55 Kg Per Week
THOMSON REUTERS  ·  45 minutes ago
Biomea Fusion: in an Additional Fifth Cohort Conducted Under Confinement, at Day 29, Mean Weight Reduction Averaged About 1.55 Kg Per Week
Biomea Fusion: Confinement Appears to Have Affected Eating Behavior for Cohort 5 Participants, Believe Its Results Should be Interpreted Separately
THOMSON REUTERS  ·  45 minutes ago
Biomea Fusion: Confinement Appears to Have Affected Eating Behavior for Cohort 5 Participants, Believe Its Results Should be Interpreted Separately
Biomea Fusion - no Increased Alt or Ast Adverse Events Reported in Bmf-650 Phase 1 Study
THOMSON REUTERS  ·  45 minutes ago
Biomea Fusion - no Increased Alt or Ast Adverse Events Reported in Bmf-650 Phase 1 Study
Biomea Fusion - All Adverse Events in Five Mad Cohorts were Mild or Moderate
THOMSON REUTERS  ·  45 minutes ago
Biomea Fusion - All Adverse Events in Five Mad Cohorts were Mild or Moderate
Biomea Fusion - Phase 1 Bmf-650 Shows 1.5%-3.2% Mean Weight Reduction at Day 29 in Cohorts 1-4
THOMSON REUTERS  ·  45 minutes ago
Biomea Fusion - Phase 1 Bmf-650 Shows 1.5%-3.2% Mean Weight Reduction at Day 29 in Cohorts 1-4
Biomea Fusion - Rapid One-Step Titration to 400 Mg Qd Well Tolerated in Cohort 5
THOMSON REUTERS  ·  45 minutes ago
Biomea Fusion - Rapid One-Step Titration to 400 Mg Qd Well Tolerated in Cohort 5
Biomea Fusion to Release Phase I Results for Oral GLP-1 Agonist BMF-650 on Oct. 13
Reuters  ·  10-13 04:31
Biomea Fusion to Release Phase I Results for Oral GLP-1 Agonist BMF-650 on Oct. 13
Biomea Fusion to Announce Phase I Results for Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
THOMSON REUTERS  ·  10-13 04:30
Biomea Fusion to Announce Phase I Results for Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Biomea Fusion Price Target Announced at $10.00/Share by Brookline Capital
Dow Jones  ·  10-07
Biomea Fusion Price Target Announced at $10.00/Share by Brookline Capital
Biomea Fusion Shares Fall After Terminating Proposed Public Offering
MT Newswires Live  ·  09-24
Biomea Fusion Shares Fall After Terminating Proposed Public Offering
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next
TIPRANKS  ·  09-24
Biomea Fusion Completes Phase 1 BMF-500 Trial in Acute Leukemia: What Investors Should Watch Next
Biomea Fusion Updates Timeline for BMF-650 Phase I Data
TIPRANKS  ·  09-23
Biomea Fusion Updates Timeline for BMF-650 Phase I Data
Biomea Fusion announces offering of common stock and warrants, no amount given
TIPRANKS  ·  09-23
Biomea Fusion announces offering of common stock and warrants, no amount given
Biomea Fusion Launches Underwritten Public Offering of Common Stock, Pre-Funded Warrants
Reuters  ·  09-23
Biomea Fusion Launches Underwritten Public Offering of Common Stock, Pre-Funded Warrants
Biomea Fusion Announces Proposed Public Offering of Securities
THOMSON REUTERS  ·  09-23
Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion - Topline Results from Phase I Glp-131 Trial for Bmf-650 Expected in October 2026 - SEC Filing
THOMSON REUTERS  ·  09-23
Biomea Fusion - Topline Results from Phase I Glp-131 Trial for Bmf-650 Expected in October 2026 - SEC Filing
Biomea Fusion to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  09-03
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next
TIPRANKS  ·  08-29
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next
Biomea Shares Rise After Completing Enrollment in Diabetes Trial
MT Newswires Live  ·  08-25
Biomea Shares Rise After Completing Enrollment in Diabetes Trial
Unusually active option classes on open August 24th
TIPRANKS  ·  08-24
Unusually active option classes on open August 24th

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--